Afya Limited Announces Entering into a Purchase Agreement for the Acquisition of Além da Medicina
Afya Limited (NASDAQ: AFYA) has announced its acquisition of 100% of Além da Medicina, an online medical content platform, through its subsidiary Afya Participações S.A. This acquisition, valued at R$16.0 million, is subject to customary conditions and involves a potential earn-out of up to R$19.2 million based on revenue targets for 2023 and 2024. Além da Medicina, which projects R$12.7 million in gross revenue for 2022, enhances Afya's digital ecosystem by providing educational tools and resources to medical professionals.
- Acquisition value of R$16.0 million expected to enhance Afya's digital education capabilities.
- Além da Medicina has an established user base and strong social media presence, with over 4,000 subscribers and nearly 100,000 Instagram followers.
- Projected gross revenue of R$12.7 million for Além da Medicina in 2022.
- Potential earn-out of R$19.2 million tied to revenue goals for 2023 and 2024.
- None.
Além da Medicina is a medical content online platform for physicians and medical students that provides educational tools besides technical medical content that can assist them throughout their careers. Its robust content includes mentoring for residency, soft skills, finance, accounting, and investment basics for physicians.
Além da Medicina had more than 4.000 subscribers in 2021, with a general NPS of 77 and almost 100.000 followers on Instagram. The company expects
This business combination incorporates new capabilities to the content & technology for the medical education pillar and further strengthens
The aggregate purchase price (enterprise value) is
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220224006088/en/
Investor Relations Contact:
ir@afya.com.br
Media Contact:
Cíntia
cintia.marin@afya.com.br
Source:
FAQ
What is the acquisition announced by Afya Limited?
How much did Afya pay for Além da Medicina?
What revenue does Além da Medicina project for 2022?
What is the potential earn-out related to the acquisition?